Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

BMJ Investigation Revives Questions About PLATO, Ticagrelor

Todd Neale

December 20, 2024

News Daily News

New Platelet Function, Genetic Testing Consensus Seeks to Fill Gaps—Again

Yael L. Maxwell

November 27, 2024

Presentation TCT 2024

TCT 505: Impact of Low-Dose Prasugrel on 1-Month and 12-Month Serial Vessel Responses After Coronary Stent Implantation

Presenter: Takayuki Ishihara

October 30, 2024

Presentation TCT 2024

TCT 426: One-Year Clinical Outcome of Prasugrel Monotherapy After PCI for Chronic Coronary Syndrome in Japanese Population

Presenter: KOTARO MIYASHITA

October 29, 2024

Presentation TCT 2024

TCT 231: Safety of Aspirin-Free Prasugrel Monotherapy After PCI: Pooled Analysis of Three Months Outcomes in 508 Patients From ASET-I and ASET-Japan Trials

Presenter: KOTARO MIYASHITA

October 27, 2024

Presentation TCT 2024

TCT 6: Aspirin-Free Prasugrel Monotherapy After PCI in Patients With Non-ST Elevation Acute Coronary Syndrome

Presenter: KOTARO MIYASHITA

October 27, 2024

News Conference News ESC 2024

More Support for Ticagrelor Monotherapy After PCI, Especially in ACS

Yael L. Maxwell

September 10, 2024

News Daily News

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

Michael O'Riordan

August 26, 2024

News Daily News

Genetic Tests for Predicting Clopidogrel Response Gain Traction: AHA

Caitlin E. Cox

June 25, 2024

News Daily News

P2Y12 Inhibitor Pretreatment Worth Considering in STEMI When PCI Is Delayed

Yael L. Maxwell

June 20, 2024

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

News Daily News

When Moving From DAPT to Monotherapy After PCI, the P2Y12 Inhibitor Matters

Yael L. Maxwell

March 21, 2024

News Daily News

UK Cardiac Audit Reveals Some Good, Some ‘Appalling’ Trends in PCI

L.A. McKeown

February 06, 2024

News Daily News

No Benefit to P2Y12 Inhibitor Pretreatment in STEMI, Bern-PCI Data Confirm

Yael L. Maxwell

January 10, 2024

News Daily News

Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2

Michael O'Riordan

January 03, 2024

Advertisement

BMJ Investigation Revives Questions About PLATO, Ticagrelor

New Platelet Function, Genetic Testing Consensus Seeks to Fill Gaps—Again

TCT 505: Impact of Low-Dose Prasugrel on 1-Month and 12-Month Serial Vessel Responses After Coronary Stent Implantation

TCT 426: One-Year Clinical Outcome of Prasugrel Monotherapy After PCI for Chronic Coronary Syndrome in Japanese Population

TCT 231: Safety of Aspirin-Free Prasugrel Monotherapy After PCI: Pooled Analysis of Three Months Outcomes in 508 Patients From ASET-I and ASET-Japan Trials

TCT 6: Aspirin-Free Prasugrel Monotherapy After PCI in Patients With Non-ST Elevation Acute Coronary Syndrome

More Support for Ticagrelor Monotherapy After PCI, Especially in ACS

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

Genetic Tests for Predicting Clopidogrel Response Gain Traction: AHA

P2Y12 Inhibitor Pretreatment Worth Considering in STEMI When PCI Is Delayed

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

When Moving From DAPT to Monotherapy After PCI, the P2Y12 Inhibitor Matters

UK Cardiac Audit Reveals Some Good, Some ‘Appalling’ Trends in PCI

No Benefit to P2Y12 Inhibitor Pretreatment in STEMI, Bern-PCI Data Confirm

Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content